Supplement researchSourced from PubMed and NIH
NutriStack
Free iPhone appUpdated September 28, 2026

Supplement × Prescription·Evidence index

Fish Oil and Rosuvastatin: what the research found

PubMed indexes 8 records that name Fish Oil and Rosuvastatin together, either in the title or in an interaction, co-administration, or pharmacokinetic context. The key findings come first, in the authors’ own words, followed by every study with its design and PubMed link.

A summary of published research, not medical advice. A pharmacist can check any combination against your full list of medicines and supplements.

Key findings

What the studies concluded.

Reviews and human studies first. Each quote is the authors’ own conclusion about their study, not a NutriStack assessment, and a single study is not a consensus.

“Patients with mixed dyslipidaemia exhibit low numbers of circulating CD34(+) and CD34(+)/KDR(+) cells as well as CFU-ECs in culture, a defect restored by 3-month treatment with either high-rosuvastatin dose or a combination of low-rosuvastatin dose with ω-3 PUFAs. The pathophysiological meaning of our results regarding the increased cardiovascular risk in these patients remains to be established.”

Chantzichristos et al. · 2016 · Human study · details

“Combined therapy with omega-3-PUFAs and rosuvastatin improves endothelial function in South Asian subjects with dyslipidemia and endothelial dysfunction.”

Mindrescu et al. · 2008 · Human study · details

“Administration of P-OM3 with rosuvastatin did not affect the pharmacokinetics of rosuvastatin under steady-state conditions in healthy individuals.”

The research

8 studies naming Fish Oil and Rosuvastatin.

Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.

Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34(+) progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia.

Atherosclerosis · 2016 · PMID 27415612

Randomized Controlled Trial

“Patients with mixed dyslipidaemia exhibit low numbers of circulating CD34(+) and CD34(+)/KDR(+) cells as well as CFU-ECs in culture, a defect restored by 3-month treatment with either high-rosuvastatin dose or a combination of low-rosuvastatin dose with ω-3 PUFAs. The pathophysiological meaning of our results regarding the increased cardiovascular risk in these patients remains to be established.”

Chantzichristos et al. · Authors' conclusion

Names both Fish Oil and Rosuvastatin in its title.

The effect of rosuvastatin alone or in combination with fenofibrate or omega-3 fatty acids on lipoprotein(a) levels in patients with mixed hyperlipidemia.

Archives of medical sciences. Atherosclerotic diseases · 2024 · PMID 38434941

“Rosuvastatin and/or fenofibrate treatment increases Lp(a) levels in patients with mixed hyperlipidemia. Novel therapies should target Lp(a) level reduction to decrease the residual ASCVD risk in patients with mixed hyperlipidemia.”

Agouridis et al. · Authors' conclusion

Names both Fish Oil and Rosuvastatin in its title.

Concomitant Use of Rosuvastatin and Eicosapentaenoic Acid Significantly Prevents Native Coronary Atherosclerotic Progression in Patients With In-Stent Neoatherosclerosis.

Circulation journal : official journal of the Japanese Circulation Society · 2020 · PMID 32759543

Comparative StudyRandomized Controlled Trial

“Compared with standard therapy, intensive therapy prevented atherosclerotic progression more effectively in native coronary plaques in patients with NA.”

Sugizaki et al. · Authors' conclusion

Names Fish Oil and Rosuvastatin together in an interaction, co-administration, or pharmacokinetic context.

Comparison table: Some lipid-lowering drugs.

The Medical letter on drugs and therapeutics · 2019 · PMID 30845107

Comparative StudyHuman subjects

Names Fish Oil and Rosuvastatin together in an interaction, co-administration, or pharmacokinetic context.

Self-nanoemulsifying drug-delivery system for improved oral bioavailability of rosuvastatin using natural oil antihyperlipdemic.

Drug development and industrial pharmacy · 2015 · PMID 25404208

Comparative StudyRandomized Controlled Trial

“Rs-SNEDDS is a promising drug delivery system for improving the drug solubility and antihyperlipidemic effect using natural oils as (olive oil and garlic oil).”

Abo Enin · Authors' conclusion

Names Fish Oil and Rosuvastatin together in an interaction, co-administration, or pharmacokinetic context.

Limitations

What this evidence cannot tell you.

Search-based evidence indexes have real limits, and it is worth being explicit about them:

How to read this page

A literature summary, not guidance.

NutriStack

Track what you actually take.

NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Fish Oil, Rosuvastatin, and several hundred other substances.

Log your routine, get reminders at the times you choose, and scan a label to add a product. The checker is a research and organisation tool, not a clinical decision aid.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.